Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

346
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
346
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Cumulative Incidence And Risk Factors Of Brain Metastases In Metastatic Non-small Cell Lung Cancer Without Baseline Brain Metastasis: Pooled Analysis Of Individualized Patient Data From Impower130, Impower131, And Impower150

Cumulative incidence and risk factors of brain metastases in metastatic non-small cell lung cancer without baseline brain metastasis: Pooled analysis of individualized patient data from IMpower130, IMpower131, and IMpower150

Yue Zhou1,2, Tiantian Guo1,2, Fei Liang3

  • 1Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.

Cancer
|February 14, 2024

Related Experiment Videos

Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging
06:44

Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging

Published on: June 7, 2020

7.3K
Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis
07:43

Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis

Published on: February 8, 2017

26.6K
Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells
05:02

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells

Published on: February 4, 2021

3.3K

View abstract on PubMed

Summary
This summary is machine-generated.

Adding atezolizumab to chemotherapy did not significantly reduce brain metastases (BMs) in metastatic non-small cell lung cancer (NSCLC) patients without initial BMs. However, bevacizumab use was associated with a reduced risk of BMs.

Area of Science:

  • Oncology
  • Medical Research
  • Clinical Trials

Background:

  • Metastatic non-small cell lung cancer (NSCLC) poses a significant risk of brain metastases (BMs).
  • Identifying preventative strategies and risk factors for BMs is crucial in NSCLC management.
  • First-line treatment options for NSCLC aim to improve outcomes and delay disease progression.

Purpose of the Study:

  • To evaluate the efficacy of atezolizumab plus chemotherapy in preventing BMs in metastatic NSCLC patients without baseline BMs.
  • To identify risk factors associated with the development of BMs in this patient population.
  • To compare the cumulative incidence of BMs between atezolizumab plus chemotherapy and chemotherapy alone.

Main Methods:

  • Pooled individual patient data from three first-line atezolizumab trials (IMpower130, IMpower131, IMpower150).
Keywords:
brain metastasis (BM)cumulative incidencenon–small cell lung cancer (NSCLC)

Related Experiment Videos

Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging
06:44

Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging

Published on: June 7, 2020

7.3K
Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis
07:43

Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis

Published on: February 8, 2017

26.6K
Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells
05:02

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells

Published on: February 4, 2021

3.3K
  • Analysis included EGFR/ALK wild-type metastatic NSCLC patients without baseline BMs.
  • Cox regression analyses were used to identify factors associated with cumulative incidence of BMs (CI-BMs).

    • Main Results:

    • No significant difference in CI-BMs was observed between the atezolizumab plus chemotherapy group (3.1%) and the chemotherapy group (3.0%) (p=0.888).
    • The cumulative incidence of BMs at 6, 12, and 24 months was 1.7%, 2.8%, and 3.3%, respectively.
    • Bevacizumab use and nonsquamous NSCLC histology were independently associated with a reduced risk of BMs.

    Conclusions:

    • First-line atezolizumab plus chemotherapy may not reduce the cumulative incidence of BMs in metastatic EGFR/ALK wild-type NSCLC patients without baseline BMs.
    • Bevacizumab administration appears to be a potential factor in reducing the risk of BMs.
    • Further research into risk stratification and targeted interventions for BMs in NSCLC is warranted.
    programmed death protein 1/programmed death ligand 1 (PD‐1/PD‐L1) inhibitors